ES8802318A1 - Morphinan derivatives - Google Patents

Morphinan derivatives

Info

Publication number
ES8802318A1
ES8802318A1 ES555200A ES555200A ES8802318A1 ES 8802318 A1 ES8802318 A1 ES 8802318A1 ES 555200 A ES555200 A ES 555200A ES 555200 A ES555200 A ES 555200A ES 8802318 A1 ES8802318 A1 ES 8802318A1
Authority
ES
Spain
Prior art keywords
denotes
atoms
hydrogen
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES555200A
Other languages
Spanish (es)
Other versions
ES555200A0 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of ES8802318A1 publication Critical patent/ES8802318A1/en
Publication of ES555200A0 publication Critical patent/ES555200A0/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Compounds of formula I < IMAGE > wherein X and Y each denote hydrogen or together denote -O-, R1 denotes allyl optionally substituted by 1 to 3 alkyl groups, the substituent or substituents having in total a maximum of 3 C-atoms, cyclopropylalkyl with 7 to 12 C-atoms, R2 denotes hydrogen, C1-10 alkyl, C5-6 cycloalkyl, or optionally substituted pheny or phenyl-C7-12 alkyl, R3 denotes hydrogen, alkyl with 1 to 10 C-atoms or phenyl, R4 denotes hydrogen, OH, NR6R7, NHCOR, NHSO2R min or NHCOOR sec , R6 and R7, independently of one another, denote hydrogen or alkyl with 1 to 3 C-atoms, R denotes alkyl with 1 to 6 C-atoms, phenyl or -A-COOR sec , A denotes alkylene or alkenylene each with 2 to 4 C-atoms, R min denotes alkyl with 1 to 6 C-atoms or phenyl, R sec denotes methyl or ethyl and wherein either R3 is in the alpha -position and R4 is in the beta -position, or R3 is in the beta -position and R4 is in the alpha -position, or R3 and R4 together are =O, or =CH2, and R5 denotes hydrogen or methyl, with the provisos that when X and Y denotes -O-, R2 denotes hydrogen, R4 denotes a alpha -OH group and R3 and R5 denote hydrogen, R1 is other than cyclopropylmethyl or allyl, and that when R2,R3,R4 and R5 are each hydrogen, R1 is other than cyclopropylmethyl, in free base form or in acid addition salt form, as well as the physiologically hydrolysable, pharmaceutically acceptable esters of such compounds, which contain a free OH group, in free base form or in acid addition salt form. The compounds according to the invention are opiate agonists/antagonists and LH secretion stimulators. Intermediates of the formula III to XIV are claimed per se.
ES555200A 1985-05-23 1986-05-21 Morphinan derivatives Expired ES8802318A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3518525 1985-05-23

Publications (2)

Publication Number Publication Date
ES8802318A1 true ES8802318A1 (en) 1988-05-01
ES555200A0 ES555200A0 (en) 1988-05-01

Family

ID=6271435

Family Applications (1)

Application Number Title Priority Date Filing Date
ES555200A Expired ES8802318A1 (en) 1985-05-23 1986-05-21 Morphinan derivatives

Country Status (18)

Country Link
JP (1) JPS61271275A (en)
AU (1) AU594954B2 (en)
BE (1) BE904796A (en)
DK (1) DK240386A (en)
ES (1) ES8802318A1 (en)
FI (1) FI862124A (en)
FR (1) FR2582309B1 (en)
GB (1) GB2175898B (en)
GR (1) GR861318B (en)
HU (1) HU196376B (en)
IL (1) IL78872A0 (en)
IT (1) IT1203791B (en)
LU (1) LU86435A1 (en)
NL (1) NL8601188A (en)
NZ (1) NZ216250A (en)
PH (1) PH23341A (en)
SE (1) SE8602308L (en)
ZA (1) ZA863873B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US4923875A (en) * 1989-07-10 1990-05-08 Baker Cummins Pharmaceuticals, Inc. Method for treatment of mast cell-mediated dermatologic disorders
JP2906654B2 (en) * 1989-11-28 1999-06-21 東レ株式会社 Immunosuppressant and method for producing the same
US5057322A (en) * 1990-08-10 1991-10-15 Baker Cummins Dermatologicals, Inc. Method of treating mast cell disease
EP0577847B1 (en) 1992-01-23 1998-10-14 Toray Industries, Inc. Morphinan derivative and medicinal use
WO1995003307A1 (en) * 1993-07-19 1995-02-02 Toray Industries, Inc. Brain cell protective
AU686203B2 (en) * 1993-07-23 1998-02-05 Toray Industries, Inc. Morphinan derivative and medicinal use
TR199801348T2 (en) * 1996-01-10 1998-10-21 Smithkline Beecham S.P.A. Heterosyclic condensate morphinoid t�revleri (II).
CN1180844C (en) * 1996-11-25 2004-12-22 东丽株式会社 Antipruritic agent
AU6117298A (en) * 1997-07-25 1999-02-16 Toray Industries, Inc. Hyponatremia remedies
US7923454B2 (en) 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
JP5438250B2 (en) 2002-05-17 2014-03-12 ジェンケン バイオサイエンスィズ，インコーポレイテッド Opioids and opioid-like compounds and their use
US7501433B2 (en) 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
JP4957489B2 (en) * 2002-10-09 2012-06-20 東レ株式会社 Pharmaceutical containing morphinan derivative having nitrogen-containing cyclic substituent or pharmacologically acceptable acid addition salt thereof
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US8354534B2 (en) * 2008-02-14 2013-01-15 Alkermes, Inc. Selective opioid compounds
WO2014091295A1 (en) * 2012-12-14 2014-06-19 Purdue Pharma L.P. Pyridonemorphinan analogs and biological activity on opioid receptors
JP6141444B2 (en) * 2012-12-14 2017-06-07 パーデュー、ファーマ、リミテッド、パートナーシップ Spirocyclic morphinans and their use
AR096851A1 (en) * 2013-07-11 2016-02-03 H Lundbeck As SALTS THAT DO NOT FORM HYDRATS OR SOLVATOS DE NALMEFENO
WO2015192053A1 (en) * 2014-06-13 2015-12-17 Purdue Pharma L.P. Azamophinan derivatives and use thereof

Also Published As

Publication number Publication date
DK240386A (en) 1986-11-24
ZA863873B (en) 1988-01-27
SE8602308D0 (en) 1986-05-21
HUT41737A (en) 1987-05-28
FI862124A0 (en) 1986-05-21
GB2175898B (en) 1989-07-05
BE904796A (en) 1986-11-21
GR861318B (en) 1986-09-19
JPS61271275A (en) 1986-12-01
IT8648050A0 (en) 1986-05-23
ES555200A0 (en) 1988-05-01
DK240386D0 (en) 1986-05-22
IL78872A0 (en) 1986-09-30
SE8602308L (en) 1986-11-24
IT1203791B (en) 1989-02-23
GB2175898A (en) 1986-12-10
PH23341A (en) 1989-07-14
FR2582309A1 (en) 1986-11-28
LU86435A1 (en) 1986-12-05
NZ216250A (en) 1990-04-26
FI862124A (en) 1986-11-24
FR2582309B1 (en) 1989-08-18
GB8612159D0 (en) 1986-06-25
NL8601188A (en) 1986-12-16
AU594954B2 (en) 1990-03-22
AU5763786A (en) 1986-11-27
HU196376B (en) 1988-11-28

Similar Documents

Publication Publication Date Title
ES8802318A1 (en) Morphinan derivatives
ES482888A1 (en) N-substituted benzimidazoles, processes for their preparation and medicines containing them.
GB2069481B (en) Substituted imidazole derivatives
ES8203845A1 (en) Pyridoxine derivatives, process for their preparation and their therapeutical use.
GR81351B (en)
IE791780L (en) Dibenzopyrans and benzoquinolines
ES8300768A1 (en) Trisubstituted pyrimido(5,4-d)pyrimidines, their preparation and medicaments containing them.
ES8700857A1 (en) Dihydropyridines.
DE3576499D1 (en) Dihydropyridine.
DE69402703D1 (en) 3- (INDOL-3-YL) PROPENIC ACID DERIVATIVES USEFUL AS NMDA ANTAGONISTS
ES471702A1 (en) Penicillin and cephalosporin preparation